29 m6A-RNA Methylation (Epitranscriptomic) Regulators Are Regulated in 41 Diseases including Atherosclerosis and Tumors Potentially via ROS Regulation – 102 Transcriptomic Dataset Analyses
Table 1
List of microarray datasets (23) of acute inflammations, metabolic diseases, autoimmune diseases, and organ failures in the NIH-NCBI-GeoDataset database (https://www.ncbi.nlm.nih.gov/gds/) we collected in this study.
GEO ID
Disease/phenotype
Tissue
Comparison
No. of samples
PMID
Acute inflammation
GSE32707
Lung injury
Whole blood
Sepsis day 0 vs. no sepsis
30/34
22461369
Lung injury
Whole blood
Sepsis day 7 vs. no sepsis
28/34
22461369
Lung injury
Whole blood
Sepsis/ARDS day 0 vs. no sepsis ARDS
18/34
22461369
Lung injury
Whole blood
Sepsis/ARDS day 7 vs. no sepsis ARDS
13/34
22461369
GSE13904
Septic shock
Whole blood
Sepsis day 1 vs. normal
32/18
19325468
Septic shock
Whole blood
Sepsis day 3 vs. normal
20/18
19325468
Septic shock
Whole blood
Sepsis/shock day 1 vs. normal
67/18
19325468
Septic shock
Whole blood
Sepsis/shock day 3 vs. normal
39/18
19325468
GSE5580
Severe trauma
Monocytes
Severe trauma vs. health
7/7
17032758
Severe trauma
Leukocytes
Severe trauma vs. health
7/7
17032758
Severe trauma
T cells
Severe trauma vs. health
7/7
17032758
Metabolic disease
GSE48964
Obese
Adipose stem cells
Morbidly obese vs. nonobese
3/3
24040759
GSE55200
MHO
Subcutaneous adipose
MHO vs. LH
8/7
24933025
MUO
Subcutaneous adipose
MUO vs. LH
8/7
24933025
GSE94752
Obese IR
Adipocytes
Obese IR vs. lean
18/9
28570579
Obese IS
Adipocytes
Obese IS vs. lean
21/9
28570579
GSE23343
T2D
Liver
T2D vs. normal glucose tolerance
10/7
21035759
GSE29221
T2D
Skeletal muscle
T2D vs. nondiabetes
12/12
23308243
GSE29226
T2D
Subcutaneous adipose
T2D vs. nondiabetes
12/12
23308243
GSE29231
T2D
Visceral adipose
T2D vs. nondiabetes
12/12
23308243
GSE28829
Atherosclerosis
Carotid artery
Advanced plaque vs. early plaque
16/13
22388324
GSE41571
Atherosclerosis
Plaque macrophages
Ruptured plaques vs. stable plaque
5/6
23122912
GSE1010
FCH
Lymphoblastic cells
FCH vs. normal
12/12
15388524
GSE6054
FHC and atherosclerosis
Monocytes
FHC homozygote vs. control
4/13
19040724
GSE6088
FHC and atherosclerosis
T cell
FHC homozygote vs. control
3/13
19040724
Autoimmune disease
GSE97779
RA
Macrophages
RA vs. normal
9/5
28813657
GSE109248
ACLE
Skin
ACL vs. normal
7/14
29889098
CCLE
Skin
CCL vs. normal
6/14
29889098
Psoriasis
Skin
Psoriasis vs. normal
17/14
29889098
SCLE
Skin
SCL vs. normal
12/14
29889098
GSE38713
UC
Sigmoid colon or rectum
UC active involved vs. normal
22/13
23135761
GSE3365
UC
PBMC
UC vs. normal
26/42
16436634
CD
PBMC
CD vs. normal
59/42
16436634
Organ failure
GSE76701
Heart failure
Left ventricle
Failing heart vs. nonfailing heart
4/4
26756417
GSE38941
HBV-ALF
Liver
HBV-ALF vs. normal
17/10
23185381
GSE37171
ESRF
Whole blood
Chronic renal failure vs. healthy controls
75/40
23809614
GSE15072
CKD hemodialysis
PBMC
Hemodialysis vs. healthy controls
17/8
19698090
Abbreviations: No. of samples: ; ARDS: acute respiratory distress syndrome; ALI: acute liver injury; ALF: acute liver failure; PBMC: peripheral blood mononuclear cell; IS: insulin sensitive; IR: insulin resistance; MHO: metabolically healthy obese; MUO: metabolically unhealthy obese; LH: lean health; T2D: type 2 diabetes; FCH: familial combined hyperlipidemia; FHC: familial hypercholesterolemia; RA: rheumatoid arthritis; ACLE: acute cutaneous lupus; CCLE: chronic cutaneous lupus; SCLE: subacute cutaneous lupus; UC: ulcerative colitis; CD: Crohn’s disease; HBV-ALF: hepatitis B virus-associated acute liver failure; ESRF: end-stage renal failure; CKD: chronic kidney disease; PBMC: peripheral blood mononuclear cell, macrophages; macrophages from synovial fluids for RA and blood-derived macrophages for control. All the studies and samples are from human.
